Steven Papish
Hematology & Oncology · Morristown, NJNPI 1811985997
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Tesaro, Inc. at 52.9% of the total. Reporting peaked in 2019 at $4,488 and has fallen 92.9% since, to $320 in 2025.
Across 82 payments — averaging $92.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tesaro, Inc.$4K
- Daiichi Sankyo Inc.$859
- Roche Diagnostics Corporation$801
- Seagen Inc.$377
- Novartis$201
- Pfizer$182
- plus $1K from 15 others
Across 172 payments — averaging $6746.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$307K
- Eli Lilly$184K
- E.r. Squibb & Sons, L.L.C.$151K
- Genentech, Inc.$117K
- Pfizer$112K
- Incyte Corporation$90K
- plus $199K from 15 others
What the payments were for
- Speaking & faculty fees$3,85051%
- Travel & lodging$491%
- Food & beverage$3,66648%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tesaro, Inc. | 4 | $4,024 |
| Daiichi Sankyo Inc. | 9 | $859 |
| Roche Diagnostics Corporation | 7 | $801 |
| Seagen Inc. | 12 | $377 |
| Novartis | 6 | $201 |
| Pfizer | 5 | $182 |
| Beigene USA, Inc. | 1 | $141 |
| Genentech USA, Inc. | 5 | $138 |
| Gilead | 7 | $132 |
| Stemline Therapeutics Inc. | 2 | $127 |
| Bristol Myers Squibb | 2 | $127 |
| Eisai Inc. | 3 | $122 |
| Biontech SE | 1 | $79 |
| AstraZeneca | 4 | $78 |
| Merck | 4 | $53 |
| E.r. Squibb & Sons, L.L.C. | 3 | $39 |
| Incyte Corporation | 2 | $35 |
| Johnson & Johnson | 2 | $28 |
| Puma Biotechnology, Inc. | 1 | $22 |
| Genentech, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEJULA$3,975
- Enhertu$232
- TUKYSA$232
- ELREXFIO$135
- NAVIFY Products$134
How this compares
$7,601 in reported general payments places this provider in the 65th percentile of 362 hematology & oncology providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 14 | $7,095 |
| Desonide | 12 | $1,367 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $53 | $7,09514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 362 hematology & oncology providers in New Jersey.
Other hematology & oncology in Morristown
- Charles FarberMorristown$609K
- Michael ScolaMorristown$506K
- Mohamad CherryMorristown$240K
- Robert SpiegelWestfield$864K
- Amit PatelJersey City$770K
- Joshua StraussSpringfield$739K
- Eshan PatelSomerville$420K
- Arturo Loaiza-BonillaPennington$406K
- Ashish ShahSpringfield$394K
- Carl HenningsonManasquan$349K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.